Patents by Inventor Satyamaheshwar Peddibhotla

Satyamaheshwar Peddibhotla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220064133
    Abstract: A method and apparatus for transferring an image of predetermined length onto a substrate by selective energization of a row of printing elements in a printhead of a printing apparatus. Operational characteristics of the printing apparatus are determined, and the image is rendered such that the number of rows of the pixels in the rendered image is no greater than the maximum number of rows of pixels which can be printed in the length of the image given the operational characteristics of the printing apparatus. Additional rows of pixels may be printed between pairs of rows of printed which correspond to consecutive rows in the rendered image. The pixel content of each additional row is a function of the pixel content of the adjacent pairs of rows.
    Type: Application
    Filed: August 12, 2019
    Publication date: March 3, 2022
    Inventors: Otto PHANSTIEL, IV, Holly MOOTS, Patrick MALONEY, Paul HERSHBERGER, Satyamaheshwar PEDDIBHOTLA
  • Patent number: 11261164
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: March 1, 2022
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Publication number: 20210300882
    Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.
    Type: Application
    Filed: June 8, 2021
    Publication date: September 30, 2021
    Applicant: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
  • Patent number: 11028061
    Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 8, 2021
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
  • Publication number: 20200354324
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: January 14, 2020
    Publication date: November 12, 2020
    Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
  • Patent number: 10584103
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: March 10, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Publication number: 20190023665
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
  • Patent number: 10118902
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 6, 2018
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Publication number: 20180222874
    Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 9, 2018
    Applicant: Sanford Bumham Prebys Medical Discovery Imstitute
    Inventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
  • Patent number: 9868707
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 16, 2018
    Assignees: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, DUKE UNIVERSITY
    Inventors: Anthony Pinkerton, Patrick Maloney, Paul Hershberger, Satyamaheshwar Peddibhotla, Michael Hedrick, Lawrence Barak, Marc Caron
  • Publication number: 20170240514
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: June 24, 2015
    Publication date: August 24, 2017
    Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
  • Publication number: 20150329497
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 19, 2015
    Applicant: DUKE UNIVERSITY
    Inventors: Anthony PINKERTON, Patrick MALONEY, Paul HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Michael HEDRICK, Lawrence BARAK, Marc CARON
  • Patent number: 7858808
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: December 28, 2010
    Assignee: Board of Trustees of Michigan State University
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
  • Publication number: 20100204260
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.
    Type: Application
    Filed: January 26, 2010
    Publication date: August 12, 2010
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
  • Patent number: 7652056
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: January 26, 2010
    Assignee: Board of Trustees of Michigan State University
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
  • Patent number: 7345078
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: March 18, 2008
    Assignee: The Board of Trustees of Michigan State University
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
  • Publication number: 20050192330
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.
    Type: Application
    Filed: April 6, 2005
    Publication date: September 1, 2005
    Applicant: Michigan State University
    Inventors: Jetze Tepe, Satyamaheshwar Peddibhotla
  • Patent number: 6878735
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: April 12, 2005
    Assignee: Board of Trustees of Michigan State University
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
  • Publication number: 20030232870
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-&kgr;B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 &mgr;m/mL.
    Type: Application
    Filed: January 17, 2003
    Publication date: December 18, 2003
    Applicant: Board of Trustees of MICHIGAN STATE UNIVERSITY
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla